Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note released on Friday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 1.5 %

NASDAQ:CHEK opened at $0.76 on Friday. The stock’s 50 day moving average price is $1.11 and its 200 day moving average price is $1.27. The company has a market capitalization of $4.46 million, a PE ratio of -0.25 and a beta of 0.16. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.45.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.